More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$383712950
EPS
-0.03
P/E ratio
--
Price to sales
2.03
Dividend yield
--
Beta
1.841018
Previous close
$1.86
Today's open
$1.85
Day's range
$1.84 - $1.94
52 week range
$1.47 - $3.47
show more
CEO
William M. Greenman
Employees
275
Headquarters
Concord, CA
Exchange
NASDAQ Global Market
Shares outstanding
201954184
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Cerus Corporation to Participate in Upcoming Investor Conferences
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management will participate in the following upcoming investor conferences. Citi's 2026 Global Healthcare Conference Format: One-on-one meetings Date: Tuesday, December 1, 2026 Location: Miami, Florida Piper Sandler 38th Annual Healthcare Conference Format: One-on-one meetings Date: Wednesday, December 2, 2026 Location: New York, New York ABOUT CERUS Cerus Corporation is dedicated so.
Business Wire • Nov 17, 2026

Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management will participate in and host one-on-one investor meetings at the 17th Annual Craig-Hallum Alpha Select Conference taking place in New York City on Tuesday, November 17. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company.
Business Wire • Nov 11, 2026

Cerus: 3 Key Takeaways for Long-Term Investors
Phase III REDeS study met primary efficacy and safety endpoints. Kit sales represented 90% of third-quarter fibrinogen complex product shipments.
The Motley Fool • Nov 3, 2026

Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript
Cerus Corporation ( CERS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Timothy Lee - Head of Investor Relation Vivek Jayaraman - CEO, President & Director Kevin Green - VP of Finance & CFO Conference Call Participants Colin Clark - TD Cowen, Research Division Mark Massaro - BTIG, LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Gabrielle Ingoglia - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Cerus Corp. Q3 2026 Earnings Conference Call.
Seeking Alpha • Nov 3, 2026

Cerus' blood-safety system meets main goal in late-stage trial
Cerus' blood-safety system meets main goal in late-stage trial
Reuters • Nov 2, 2026

Cerus Q3 Earnings Call Highlights
Cerus NASDAQ: CERS reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III RedeS study of pathogen-reduced red blood cells.
MarketBeat • Nov 3, 2026

Cerus Corporation Announces Third Quarter 2026 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update. "Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end,” said Vivek Jayaraman, Cerus's president and chief executive officer. “Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation.
Business Wire • Nov 2, 2026

Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results from the Phase 3 RedeS (NCT03037164) trial. “Over the past decade, pathogen reduction technology has become an integral component of the blood safety toolkit. The topline results from the RedeS study reinforce the potential to extend this established paradigm to red blood cell transfusions,” said Ross M. Fasano, MD, Professor of Pathology & Laboratory Medicine and Hematology at Emory.
Business Wire • Nov 2, 2026

Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati.
Business Wire • Oct 19, 2026

Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from aroun.
Business Wire • Oct 14, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Cerus Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.